(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/234417 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 31/16* (2006.01)
A61K 9/127 (2006.01)

(21) International Application Number:
PCT/IB2022/053995

(22) International Filing Date:
29 April 2022 (29.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/183,624	03 May 2021 (03.05.2021)	US
63/184,201	04 May 2021 (04.05.2021)	US
63/197,325	04 June 2021 (04.06.2021)	US
63/261,784	28 September 2021 (28.09.2021)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **ALLEN, Pirada Suphaphiphat**; c/o Pfizer Inc., 401 North Middletown Road, Pearl River, New York 10965 (US). **BADKAR, Advait Vijay**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **DARVARI, Ramin**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **DORMITZER, Philip Ralph**; 73 Old Orchard Road, Sherborn, Massachusetts 01770 (US). **DUDA, Mark**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US). **JANSEN, Kathrin Ute**; c/o Pfizer Inc., 401 North Middletown Road, Pearl River, New York 10965 (US). **VAN GEEN HOVEN, Christina**; c/o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: IMMUNOGENIC COMPOSITION AGAINST INFLUENZA

(57) Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

WO 2022/234417 A1